(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 77.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Bridgebio Pharma's revenue in 2025 is $235,812,000.On average, 7 Wall Street analysts forecast BBIO's revenue for 2025 to be $88,129,636,187, with the lowest BBIO revenue forecast at $83,821,653,949, and the highest BBIO revenue forecast at $93,003,477,196. On average, 7 Wall Street analysts forecast BBIO's revenue for 2026 to be $154,015,287,585, with the lowest BBIO revenue forecast at $130,447,652,074, and the highest BBIO revenue forecast at $199,828,437,231.
In 2027, BBIO is forecast to generate $260,803,160,930 in revenue, with the lowest revenue forecast at $216,383,629,678 and the highest revenue forecast at $340,834,325,782.